ID   HepG2-CAR
AC   CVCL_XI50
DR   cancercelllines; CVCL_XI50
DR   Wikidata; Q94103341
RX   Patent=US20190256822;
CC   Population: Caucasian.
CC   Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Leu (c.182A>T); ClinVar=VCV000375874; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line).
CC   Transfected with: HGNC; 7969; NR1I3.
CC   Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR).
CC   Derived from site: In situ; Liver; UBERON=UBERON_0002107.
DI   NCIt; C3728; Hepatoblastoma
DI   ORDO; Orphanet_449; Hepatoblastoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0027 ! Hep-G2
SX   Male
AG   15Y
CA   Cancer cell line
DT   Created: 19-12-19; Last updated: 05-10-23; Version: 9
//
RX   Patent=US20190256822;
RA   van der Mark V.A.;
RT   "Hepatic cell line resistant to dimethyl sulfoxide, cell culture and
RT   uses thereof.";
RL   Patent number US20190256822, 22-Aug-2019.
//